After years of aggressive expansion, the clinical trial site network sector experienced a sharp correction in 2024. The dramatic drop in vaccine trial activity following the COVID-19 pandemic surge has reshaped the competitive landscape. This fourth installment in our Scaling and Innovating series reveals which networks weathered the storm and what strategies positioned them for success in a post-pandemic market.
What This Report Covers
Market Correction
- The first significant revenue decline since investors entered the space
- How the vaccine downturn impacted network performance
- Winners vs. losers: what separated them
Strategic Shifts
- Networks adapting to reduced vaccine trial volume
- The rise of cardio-metabolic research as a growth area
- Diversification strategies for long-term stability
Looking Ahead
- The “new normal” for site networks
- Key trends shaping the future
- What to watch for going forward